Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
OptimizeRx Corp. (OPRX)
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
$8.67-11.71%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
1.08 → 1.04 EPS · FY ending Dec 31, 2027 · 4 analysts
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 5, 2026 to Nov 4, 2026: (new ÷ prior − 1). Contributor count changed from 4 to 4; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for OPRX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Achieve adjusted EBITDA guidance of $21M-$25M for FY26 | The company targets adjusted EBITDA near $23 million. | Intact | adjusted EBITDA falls below $21 million in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
OPRX is a high-risk growth business with strong recent performance but ongoing losses. Its long-term thesis is intact, though the latest signal has shifted from mildly favorable to mixed.
The evidence labels valuation as expensive, while also showing OPRX as cheap versus peers, so the relative valuation picture is mixed. The priced-in tag is justified, with no fragility gates triggered, but the expectations gap is negative and confidence in the valuation model is medium.
Near term, revenue and adjusted EBITDA are under pressure: second-quarter revenue fell year over year, and adjusted EBITDA declined. Management reiterated its 2026 guidance and has paid down debt, but the revenue goal remains a meaningful execution test; the latest earnings event was positive, while a CFO transition adds a management change to watch.
The multi-year view hinges on whether customer investment and commercial momentum support management’s 2026 revenue guidance while margins and debt continue to improve. A guidance cut or further weakening in jobs could weigh on the business outlook, while continued strength among healthcare sector bellwethers could support the sector backdrop.
Over the next 1 to 3 years, OPRX combines strong recent performance and debt reduction with losses, high risk, and near-term revenue pressure. The long-term thesis depends on management delivering its guidance and sustaining commercial momentum. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| It has announced share buybacks and seeks to improve cash flow. |
| Improving |
| cash from operations remains negative or worsens over next 4 quarters |
Cash from operations: $8.611M FY2026-Q2; GAAP. Published target: cash from operations improves to positive territory. Target period is not explicitly aligned with this observation. Aug 13, 20268,611,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve revenue guidance of $109M-$114M for FY26 | A primary condition in OptimizeRx Corp.'s published investment case. The stated target is >= $109 million and <= $114 million. | Intact | revenue falls below $109 million in FY26 | Revenue: $20.504M FY2026-Q2; GAAP. Published target: >= $109 million and <= $114 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 13, 202620,504,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$1.09 → $1.04 · observed estimates
$0.11B → $0.11B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-07-25 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-07-26 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-07-27 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-07-28 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-07-29 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-07-30 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-07-31 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-01 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-02 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-08-03 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-08-04 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-05 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-06 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-07 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-08 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-08-09 | $1.09 | $108,894,830 | 5 / 6 |
| 2026-08-10 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-12 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-13 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-14 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-15 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-16 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-17 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-18 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-19 | $1.09 | $108,894,880 | 4 / 5 |
| 2026-08-20 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-21 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-22 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-23 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-24 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-25 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-26 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-27 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-28 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-29 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-30 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-08-31 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-01 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-02 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-03 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-04 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-05 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-06 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-07 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-08 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-09 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-10 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-11 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-12 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-13 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-14 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-15 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-16 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-17 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-18 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-19 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-20 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-21 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-22 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-23 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-24 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-25 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-26 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-27 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-28 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-29 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-09-30 | $1.10 | $107,636,333 | 3 / 5 |
| 2026-10-01 | $1.08 | $106,554,833 | 3 / 5 |
| 2026-10-02 | $1.08 | $106,554,833 | 3 / 5 |
| 2026-10-03 | $1.08 | $106,554,833 | 4 / 5 |
| 2026-10-04 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-05 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-06 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-07 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-08 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-09 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-10 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-11 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-12 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-13 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-14 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-15 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-16 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-17 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-18 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-19 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-20 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-21 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-22 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-23 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-24 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-25 | $1.08 | $106,595,500 | 4 / 5 |
| 2026-10-26 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-10-27 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-10-28 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-10-29 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-10-30 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-10-31 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-11-01 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-11-02 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-11-03 | $1.04 | $106,595,500 | 4 / 5 |
| 2026-11-04 | $1.04 | $106,595,500 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 6 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.